' fill='%23ffffff'%3E%3Cpath d='M283.94,167.31l386.39,516.64L281.5,1104h87.51l340.42-367.76L984.48,1104h297.8L874.15,558.3l361.92-390.99 h-87.51l-313.51,338.7l-253.31-338.7H283.94z M412.63,231.77h136.81l604.13,807.76h-136.81L412.63,231.77z'%3E%3C/path%3E%3C/g%3E%3C/svg%3E%0A){kind=small}
Research Areas
- Ageing
- Anaesthesia, Perioperative Medicine, and Critical Care
- Cancer
- Cardiovascular
- COVID-19
- Dermatology
- Diabetes
- Ear, Nose and Throat
- Gastroenterology
- Genetics and Rare Diseases
- Haematology
- Hepatology
- Infectious Diseases
- Mental Health
- Metabolic and Endocrine
- Musculoskeletal Health
- Neuroprogressive and Dementia Network
- Ophthalmology
- Oral and Dental
- Paediatrics
- Pain
- Primary Care
- Regenerative Medicine
- Renal
- Reproductive Health and Childbirth
- Respiratory
- Stroke
- Transplant
- Trauma and Emergencies
Neuroprogressive and Dementia Research Information
The Neuroprogressive & Dementia Network makes available a range of information to support and promote clinical research activity in Scotland.
Quarterly Newsletters Show more Show less
The Network produces a quarterly newsletter to give updates on the activities that the Network has been involved with and also the studies they are actively recruiting participants for.
If you would like to be on the distribution list for this newsletter, please email tay.ndntayside@nhs.scot or call 01382 423086.
Newsletters
News Stories Show more Show less
News and updates from across the Neuroprogressive and Dementia Network.
April 2025
- What makes a good clinical trial research team?
- LGBTQ+ and higher dementia risk
- Neuroprogressive and Dementia Network support helps to identify priorities for inclusive future studies
March 2025
- What I wish I knew before working in Clinical Trials
- Neuroprogressive & Dementia Network part of global MSA study success as one of four UK sites
- My First Clinical Trial: Lessons Learned
February 2025
- Parkinson study results: "Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial"
- 1,000 volunteers research milestone within reach for Neuroprogressive and Dementia Network
November 2024
September 2024
August 2024
Academic Publications Show more Show less
Academic papers written by the NDN staff.
- Patient and public involvement in dementia and neuroprogressive conditions: commentary from NHS Scotland based ‘partners in research’ — Dr Rosalie Ashworth, Dr Tom Russ, Jacqueline Kerr
Brain Awareness Week 2025 Show more Show less
During Brain Awareness Week (10-16 March 2025) our Senior Team, and also some Partners in Research, recorded some videos to talk about how important it is that Neuroprogressive disease research is funded:
